Novavax awaits one more signature from the CDC before it can be used for public use.
“Today’s authorization offers adults in the United States who have not yet received a COVID-19 vaccine another option that meets the FDA’s rigorous standards for safety, effectiveness and manufacturing quality needed to support emergency use authorization,” FDA Commissioner Robert Califf, MD, said in a statement.
Barely two-thirds of the nation is fully vaccinated against COVID-19, according to CDC estimates.
The two-dose adjuvanted series — which is an ingredient typical for vaccines intended to boost immune responses — has a 90.4 percent efficacy rate in adults.
Two days before the authorization, the federal government ordered 3.2 million doses of the vaccine in anticipation of the FDA giving the OK.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.